Header

UZH-Logo

Maintenance Infos

Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia


Baumann, Philipp; Fouzas, Sotirios; Pramana, Isabelle; Grass, Beate; Niesse, Oliver; Bührer, Christoph; Spanaus, Katharina; Wellmann, Sven (2015). Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia. Neonatology, 108(4):293-296.

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) is a common complication in preterm infants. Clinical prediction of BPD at an early stage in life is difficult. Plasma proendothelin-1 (CT-proET-1) is a lung injury biomarker in pulmonary hypertension and respiratory distress.
OBJECTIVE: To assess the prognostic ability of CT-proET-1 in BPD.
METHODS: In 227 prospectively enrolled preterm infants born at <32 weeks gestational age (GA), plasma CT-proET-1 was measured at birth, day of life (DOL) 2, 3, 6 and 28, and at 36 weeks postmenstrual age (PMA). BPD was defined as mild in infants requiring supplemental oxygen at DOL 28 and moderate/severe in those requiring it at 36 weeks PMA.
RESULTS: The predictive ability of CT-proET-1 for any BPD was poor at birth [area under the ROC curve (AUC) 0.654, 95% CI 0.494-0.814], moderate at DOL 2 and 3 (AUC 0.769, 95% CI 0.666-0.872) and excellent at DOL 6 (AUC 0.918, 95% CI 0.840-0.995). Multivariable regression analysis revealed that CT-proET-1 levels at DOL 2, 3, 6 and 28 were strongly related to the duration of oxygen supplementation, independently of GA and the duration of respiratory support.
CONCLUSIONS: CT-proET-1 is a novel promising biomarker for predicting the development of BPD in preterm infants when measured at the end of the first week of life.

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) is a common complication in preterm infants. Clinical prediction of BPD at an early stage in life is difficult. Plasma proendothelin-1 (CT-proET-1) is a lung injury biomarker in pulmonary hypertension and respiratory distress.
OBJECTIVE: To assess the prognostic ability of CT-proET-1 in BPD.
METHODS: In 227 prospectively enrolled preterm infants born at <32 weeks gestational age (GA), plasma CT-proET-1 was measured at birth, day of life (DOL) 2, 3, 6 and 28, and at 36 weeks postmenstrual age (PMA). BPD was defined as mild in infants requiring supplemental oxygen at DOL 28 and moderate/severe in those requiring it at 36 weeks PMA.
RESULTS: The predictive ability of CT-proET-1 for any BPD was poor at birth [area under the ROC curve (AUC) 0.654, 95% CI 0.494-0.814], moderate at DOL 2 and 3 (AUC 0.769, 95% CI 0.666-0.872) and excellent at DOL 6 (AUC 0.918, 95% CI 0.840-0.995). Multivariable regression analysis revealed that CT-proET-1 levels at DOL 2, 3, 6 and 28 were strongly related to the duration of oxygen supplementation, independently of GA and the duration of respiratory support.
CONCLUSIONS: CT-proET-1 is a novel promising biomarker for predicting the development of BPD in preterm infants when measured at the end of the first week of life.

Statistics

Altmetrics

Downloads

0 downloads since deposited on 18 Jan 2016
24 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neonatology
04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
04 Faculty of Medicine > University Hospital Zurich > Institute of Clinical Chemistry
Dewey Decimal Classification:610 Medicine & health
540 Chemistry
Language:English
Date:2015
Deposited On:18 Jan 2016 11:40
Last Modified:08 Dec 2017 16:59
Publisher:Karger
ISSN:1661-7800
Publisher DOI:https://doi.org/10.1159/000438979
PubMed ID:26355291

Download

Download PDF  'Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia'.
Preview
Content: Published Version
Filetype: PDF
Size: 227kB
View at publisher